302 related articles for article (PubMed ID: 30712978)
41. Involvement of Advanced Glycation End Products in the Pathogenesis of Diabetic Retinopathy.
Xu J; Chen LJ; Yu J; Wang HJ; Zhang F; Liu Q; Wu J
Cell Physiol Biochem; 2018; 48(2):705-717. PubMed ID: 30025404
[TBL] [Abstract][Full Text] [Related]
42. AGEs, RAGEs and s-RAGE; friend or foe for cancer.
Ahmad S; Khan H; Siddiqui Z; Khan MY; Rehman S; Shahab U; Godovikova T; Silnikov V; Moinuddin
Semin Cancer Biol; 2018 Apr; 49():44-55. PubMed ID: 28712719
[TBL] [Abstract][Full Text] [Related]
43. AGE-RAGE axis blockade in diabetic nephropathy: Current status and future directions.
Sanajou D; Ghorbani Haghjo A; Argani H; Aslani S
Eur J Pharmacol; 2018 Aug; 833():158-164. PubMed ID: 29883668
[TBL] [Abstract][Full Text] [Related]
44. Serum levels of advanced glycation end-products (AGEs) and the decoy soluble receptor for AGEs (sRAGE) can identify non-alcoholic fatty liver disease in age-, sex- and BMI-matched normo-glycemic adults.
Palma-Duran SA; Kontogianni MD; Vlassopoulos A; Zhao S; Margariti A; Georgoulis M; Papatheodoridis G; Combet E
Metabolism; 2018 Jun; 83():120-127. PubMed ID: 29409822
[TBL] [Abstract][Full Text] [Related]
45. Advanced glycation end products and their receptor in age-related, non-communicable chronic inflammatory diseases; Overview of clinical evidence and potential contributions to disease.
Reynaert NL; Gopal P; Rutten EPA; Wouters EFM; Schalkwijk CG
Int J Biochem Cell Biol; 2016 Dec; 81(Pt B):403-418. PubMed ID: 27373680
[TBL] [Abstract][Full Text] [Related]
46. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes.
Yamagishi S; Matsui T; Nakamura K
Curr Drug Targets; 2007 Oct; 8(10):1138-43. PubMed ID: 17979674
[TBL] [Abstract][Full Text] [Related]
47. Nutrient-Induced Inflammation in Polycystic Ovary Syndrome: Role in the Development of Metabolic Aberration and Ovarian Dysfunction.
González F
Semin Reprod Med; 2015 Jul; 33(4):276-86. PubMed ID: 26132932
[TBL] [Abstract][Full Text] [Related]
48. Molecular & genetic factors contributing to insulin resistance in polycystic ovary syndrome.
Mukherjee S; Maitra A
Indian J Med Res; 2010 Jun; 131():743-60. PubMed ID: 20571162
[TBL] [Abstract][Full Text] [Related]
49. Impact of advanced glycation end products (AGEs) signaling in coronary artery disease.
Kosmopoulos M; Drekolias D; Zavras PD; Piperi C; Papavassiliou AG
Biochim Biophys Acta Mol Basis Dis; 2019 Mar; 1865(3):611-619. PubMed ID: 30611860
[TBL] [Abstract][Full Text] [Related]
50. Role of vitamin D in ovarian physiology and its implication in reproduction: a systematic review.
Irani M; Merhi Z
Fertil Steril; 2014 Aug; 102(2):460-468.e3. PubMed ID: 24933120
[TBL] [Abstract][Full Text] [Related]
51. Insulin resistance in skeletal muscle and adipose tissue in polycystic ovary syndrome: are the molecular mechanisms distinct from type 2 diabetes?
Corbould A
Panminerva Med; 2008 Dec; 50(4):279-94. PubMed ID: 19078869
[TBL] [Abstract][Full Text] [Related]
52. Activation of the receptor for advanced glycation end products and consequences on health.
Wautier MP; Guillausseau PJ; Wautier JL
Diabetes Metab Syndr; 2017; 11(4):305-309. PubMed ID: 27612394
[TBL] [Abstract][Full Text] [Related]
53. Oxidative stress and cardiovascular complications in polycystic ovarian syndrome.
Hyderali BN; Mala K
Eur J Obstet Gynecol Reprod Biol; 2015 Aug; 191():15-22. PubMed ID: 26066290
[TBL] [Abstract][Full Text] [Related]
54. Advanced Glycation End Products (AGEs) May Be a Striking Link Between Modern Diet and Health.
Gill V; Kumar V; Singh K; Kumar A; Kim JJ
Biomolecules; 2019 Dec; 9(12):. PubMed ID: 31861217
[TBL] [Abstract][Full Text] [Related]
55. Multi-system reproductive metabolic disorder: significance for the pathogenesis and therapy of polycystic ovary syndrome (PCOS).
Li Y; Chen C; Ma Y; Xiao J; Luo G; Li Y; Wu D
Life Sci; 2019 Jul; 228():167-175. PubMed ID: 31029778
[TBL] [Abstract][Full Text] [Related]
56. Modulatory role of HMG-CoA reductase inhibitors and ezetimibe on LDL-AGEs-induced ROS generation and RAGE-associated signalling in HEK-293 Cells.
Nabi R; Alvi SS; Shah A; Chaturvedi CP; Iqbal D; Ahmad S; Khan MS
Life Sci; 2019 Oct; 235():116823. PubMed ID: 31476307
[TBL] [Abstract][Full Text] [Related]
57. Metabolic syndrome enhances endoplasmic reticulum, oxidative stress and leukocyte-endothelium interactions in PCOS.
Bañuls C; Rovira-Llopis S; Martinez de Marañon A; Veses S; Jover A; Gomez M; Rocha M; Hernandez-Mijares A; Victor VM
Metabolism; 2017 Jun; 71():153-162. PubMed ID: 28521868
[TBL] [Abstract][Full Text] [Related]
58. Selective ovary resistance to insulin signaling in women with polycystic ovary syndrome.
Wu XK; Zhou SY; Liu JX; Pöllänen P; Sallinen K; Mäkinen M; Erkkola R
Fertil Steril; 2003 Oct; 80(4):954-65. PubMed ID: 14556818
[TBL] [Abstract][Full Text] [Related]
59. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis.
Dunaif A
Endocr Rev; 1997 Dec; 18(6):774-800. PubMed ID: 9408743
[TBL] [Abstract][Full Text] [Related]
60. Insulin resistance in polycystic ovarian disease.
Bhatia V
South Med J; 2005 Sep; 98(9):903-10; quiz 911-2, 923. PubMed ID: 16217983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
